Durable Clinical Response of Advanced Lung Adenocarcinoma Harboring EGFR-19del/T790M/BRAF(V600E) Mutations After Treating with Osimertinib and Dabrafenib Plus Trametinib: A Case Report

EGFR-T790M and BRAF(V600E) are the common resistance mechanisms to EGFR-tyrosine kinase inhibitors (TKIs). Standard treatment for the triple mutations of EGFR-19del, T790M, and BRAF(V600E) is still under debate. Herein, we present a case of therapeutic efficacy of osimertinib and dabrafenib plus tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Honggang, Zhuang, Zhenjie, Xie, Jingyi, Huang, Haifu, Tao, Zhigang, Liu, Zhanhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428409/
https://www.ncbi.nlm.nih.gov/pubmed/32848419
http://dx.doi.org/10.2147/OTT.S240775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428409/
https://www.ncbi.nlm.nih.gov/pubmed/32848419
http://dx.doi.org/10.2147/OTT.S240775

Ejemplares similares